Member Info for wherethefoxhat

Https://www.thisismoney.co.uk/money/markets/article-15882373/SMALL-CAP-IDEA-Poolbeg-Pharma-oral-drug-unlock-cancer-immunotherapys-biggest-problem.html?ico=mol_desktop_home-newtab&molReferrerUrl=https%3A%2F%2Fwww.dailymail.com%2Fhome%2Findex.html

Usualy when a short drops out the price goes up with a jolt !

Kings Peach

OH YES

Does anyone using Tradingview know is there a buletin board ?

Does training view have a buletin board ?

Hi

question

what is best website other than ADVFN for simply UK & US portfolio tracking with option of live (not delayed ) pricing

will still use LSE but obviously but no app and they dont do US

How come the indicated buys and sells for this trade on ADVFN appear to be very close

is it manipulation do you think

Https://www.dailymail.co.uk/health/article-15600501/Prostate-patients-tumours-shrink-remarkable-trial-new-treatment.html?ito=push-notification&ci=RwSJbGbWLn&cri=5PB4shpaJ-&si=Idfb1QCLyqb1&xi=84435736-10b6-4628-9dc2-d2f8a3fa9709&ai=15600501

And the opinion gauge says ...............................????????????????

what

Why post that again

its nearly 2 years old

1 million buy !!!!!!!!!!!

Or is it a Southfork Range shower moment that ive just had ?

Nipah is known for its high fatality rate of 40 to 75 per cent, though this varies between outbreaks depending on how quickly patients are diagnosed and how strong clinical care and surveillance are in affected areas.

In the worst cases, Nipah can be a rapid and brutal illness because it can cause severe inflammation of the brain (encephalitis) and acute respiratory failure.

Amazon's grocery channel

The company's online grocery business has exploded to over $150 billion in gross sales, serving more than 150 million customers annually. That's made Amazon one of the top three grocers in the U.S.

clear as day to me

here they come for Ocado

£1.06 target

Avacta is approaching a defining period, with the imminent Phase I start of its second asset AVA6103 (FAP-EXd), a sustained release pre|CISION-exatecan conjugate. Initial data by year-end, as well as first breast cancer data for lead asset faridoxorubicin (AVA6000, FAP-Dox) could crystallise partnering interest. The utility, and value, of the pre|CISION platform is becoming clearer as growing preclinical and clinical data confirm its ability to improve the therapeutic index of many highly potent yet systemically toxic oncology drugs. Advances in pre|CISION chemistry, employing capping groups and novel linkers, have the potential to expand applicability of this technology to a wider range of payloads and cancer types. Newly unveiled novel dual payload PDC platform AVA6207 exemplifies Avacta’s skillset and ambition. Pipeline progress into the clinic and successful clinical results over the next 24 months should provide multiple value-inflection points. We value Avacta at £468m, or 106p/share.

Why the >no opinion< ?

i think you be foolin us

Halda having presented stage 1 data only in October 2025

.